4//SEC Filing
Feder Julie B 4
Accession 0000950170-23-060493
CIK 0001501796other
Filed
Nov 6, 7:00 PM ET
Accepted
Nov 7, 6:09 PM ET
Size
8.6 KB
Accession
0000950170-23-060493
Insider Transaction Report
Form 4
Feder Julie B
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2023-11-06$2.74/sh+3,900$10,686→ 73,500 total - Exercise/Conversion
Stock Option (Right to Buy)
2023-11-06−3,900→ 85,757 totalExercise: $2.74Exp: 2028-10-03→ Common Stock (3,900 underlying) - Sale
Common Stock
2023-11-06$12.07/sh−3,900$47,054→ 69,600 total
Footnotes (3)
- [F1]The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated June 23, 2023 previously adopted by the reporting person.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This option is fully vested.
Documents
Issuer
Aura Biosciences, Inc.
CIK 0001501796
Entity typeother
Related Parties
1- filerCIK 0001710237
Filing Metadata
- Form type
- 4
- Filed
- Nov 6, 7:00 PM ET
- Accepted
- Nov 7, 6:09 PM ET
- Size
- 8.6 KB